THE OBJECT OF THIS PROJECT IS TO PRODUCE A KIT THAT UTILIZES ANTI-CSAP MONOCLONAL ANTIBODIES (MABS) FOR CLINICAL RADIOIMMUNODETECTION (RAID) OF COLORECTAL AND PANCREATIC CANCERS.

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 3059
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1985
Solitcitation Year: N/A
Solitcitation Topic Code: N/A
Solitcitation Number: N/A
Small Business Information
Immunomedics, Inc.
100 Bergen Street Bldg. #5, Newark, NJ, 07103
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 DAN SHOCHAT
 PRINCIPAL INVESTIGATOR
 (201) 456-4779
Business Contact
Phone: () -
Research Institution
N/A
Abstract
THE OBJECT OF THIS PROJECT IS TO PRODUCE A KIT THAT UTILIZES ANTI-CSAP MONOCLONAL ANTIBODIES (MABS) FOR CLINICAL RADIOIMMUNODETECTION (RAID) OF COLORECTAL AND PANCREATIC CANCERS. PHASE I WILL BE DEVOTED TO SELECTION OF HYBRIDOMAS WITH SPECIFICITY TO CSAP, AND MABS THAT ARE SUITABLE FOR IMAGING. IT WILL BE ACHIEVED BY INVESTIGATING THEIR IN VIVO DISTRIBUTION IN TUMOR AND NONTUMOR TISSUES USING AN ANIMAL MODEL. PHASE II INVOLVES: 1.SELECTION OF SUITABLE IRRELEVANT ANTIBODIES FOR SUBTRACTION. 2.RAID OF XENOTRANSPLANTED HUMAN TUMORS IN ANIMAL MODELS BY SUBTRACTION, USING I-131 AND I-123 TO LABEL THE SPECIFIC AND IRRELEVANT MABS RESPECTIVELY. 3.COMPARISON OF THE IMAGING EFFICIENCY OF A SINGLE ANTI-CSAP MAB TO THAT OF: A.POLYCLONAL ANTI-CSAP ANTIBODIES; C.ANTI-CEA MABS; AND D.MIXTURES OF ANTI-CSAP AND ANTI-CEA MABS. PRELIMINARY CLINICAL RAID STUDIES WITH ANTI-CSAP MABS ARE EXPECTED AT THE END OF THIS PHASE.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government